199results about How to "Good potency" patented technology

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an A.beta..sub.42 lowering agent to a mammal under conditions in which levels of A.beta..sub.42 are selectively reduced, levels of A.beta..sub.38 are increased, and levels of A.beta..sub.40 are unchanged. The invention provides methods and materials for developing and identifying A.beta..sub.42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of A.beta..sub.42 lowering agents and antioxidants, A.beta..sub.42 lowering agents and non-selective secretase inhibitors, as well as A.beta..sub.42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and / or acetylcholinesterase inhibitors as well as instructions related to dose regimens for A.beta..sub.42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3′, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.

The invention pertains to using double stranded ribonucleic acid molecules such as small interfering RNA (siRNA) molecules to target an SOD gene to interfere with gene expression and SOD protein production. Method are disclosed for inhibiting expression of a target protein in a subject with a neurological disorder by introducing a small interference ribonucleic acid (siRNA) molecule into the subject with the neurological disorder, such as amyotrophic lateral sclerosis (ALS).

Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≧95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

The invention describes compositions that include a stevia sweetener and a salt of a steviol glycoside, wherein the concentration of the components provide an improved taste profile where bitterness, after taste and / or lingering of the stevia sweetener is decreased or eliminated.

This invention relates to the use of a composition comprising a polysaccharide and a botulinum toxin for reducing a skin wrinkle. In some embodiments, the polysaccharide comprises disaccharides. In some embodiments, the average molecular weight of a disaccharide unit of the polysaccharide is between about 345 D and about 1,000 D.

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and materials for developing and identifying Aβ42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ42 lowering agents and antioxidants, Aβ42 lowering agents and non-selective secretase inhibitors, as well as Aβ42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and / or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted at the 4-position. In comparison to artemisinin semisynthetic derivatives, the compounds of this invention are structurally simple, easy to synthesize, non-toxic, and potent against malarial parasites.

The invention discloses a method for the solid state fermentation processing treatment of a Chinese traditional medicine, which is characterized in that the method comprises the steps of the screening and acclimation of Chinese medicine fermentation medical microbes, the preparation of Chinese medicine solid state fermentation culture medium and the solid state fermentation processing of the Chinese medicine. In the method, the solid state fermentation of the microbes is used as a method for processing the Chinese medicine, thereby breaking the limitation that the prior solid state fermentation Chinese medicine processing is mainly the self fermentation of fungus Chinese medicine and widening the source of the fungus species for the Chinese medicine solid state fermentation processing. Moreover, the method fully utilizes the microbe conversion and biological catalytic action, improves chemical compositions and the efficacy of the Chinese medicine compound and promoting the Maillard reaction of the Chinese medicine compound.

Production of triazophosphous artificial semi-antigen, antigen and antibody is carried out by taking O-ethyl thiophsphoryl dichloride as material, reacting O-ethyl thiophsphoryl dichloride with synthetic intermediate 1-phenyl-1,2,4-triazoalcohol of triazophosphous under catalyst action, generating monochloride, reacting monochloride with propalanine under acid-binding agent action, generating triazophosphous semi-antigen TZLBu, reacting monochloride with amino acetic acid under acid-binding agent action, generating TZLHe, coupling with protein by carbodi-imide method and mixed acid anhydride method, and obtaining artificial antigen. Its advantages include rapid, convenient, low cost, and specific antibody with high affinity.

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and materials for developing and identifying Aβ42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ42 lowering agents and antioxidants, Aβ42 lowering agents and non-selective secretase inhibitors, as well as Aβ42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and / or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

The invention provides a heatproof lyoprotectant for a live vaccine against pseudorabies. The heatproof lyoprotectant comprises, by weight, 3 to 10 parts of gelatin, 1 to 5 parts of trehalose, 5 to 15 parts of sucrose, 0.1 to 2 parts bovine serum albumin, 1 to 8 parts of tryptone, 2 to 10 parts of enzyme-hydrolyzed casein, 1 to 5 parts of thiourea, 0.8 to 2 parts of L-monosodium glutamate, 0.1 to 3 parts of arginine, 0.5 to 5 parts of polyvinylpyrrolidone (PVP-K30) and 0.1 to 2 parts of mannitol. The invention also discloses a preparation method of the heatproof lyoprotectant and a lyophilized vaccine prepared from the heatproof lyoprotectant. When the heatproof lyoprotectant is used for protecting the vaccine and a specific lyophilization process is employed, lyophilization loss of viruses can be effectively reduced, the temperature tolerance of the viruses can be improved, and the vaccine can still maintain good physical properties and titer after long-term storage; i.e., the vaccine has stable characters and has the characteristics of heat resistance and long storage time.

Provided are bifunctional compounds comprising a poly(ADP-ribose) polymerase (PARP) inhibitor moiety and a reactive oxygen species (ROS) scavenger moiety, more particularly, a lipoic acid or cyclic nitroxide derivative, covalently attached either directly or via a linker, as well as pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful for prevention, treatment, or management of diseases, disorders and conditions associated with elevated PARP activity or expression.

The invention discloses a hapten, and a preparation method and application thereof, particularly a methyl parathion hapten. The invention also discloses a preparation method and application of the hapten. The kit quick detection product established on the basis of the methyl parathion hapten is convenient to use and low in detection cost; and the detection method is efficient, accurate and quick, can be used for simultaneously detecting mass samples, and is suitable for on-site supervision of methyl parathion residues in corn and apple samples and screening of mass samples.

The invention discloses a CyHV-2 (Cyprinid Herpesvirus 2) monoclonal antibody, a hybridoma cell and an application of the CyHV-2 monoclonal antibody. The CyHV-2 monoclonal antibody disclosed by the invention is secreted from a hybridoma cell GFHNV-6G7 with the collection number of CCTCC No. C2013114 or hybridoma cell GFHNV-3B5 with the collection number of CCTCC No. C2013115. The CyHV-2 monoclonal antibody disclosed by the invention has good specificity and potency; by producing rapid immunodetection test paper from the CyHV-2 monoclonal antibody, the speed and efficiency of detection can be increased, and field detection on CyHV-2 can be realized. The CyHV-2 monoclonal antibody disclosed by the invention makes up the blank in immunodetection on the CyHV-2 and lays a foundation for immunological research on the CyHV-2.

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.

Compounds of formula I:where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X is CH2, O or S, and n is 1, 2 or 3, with the proviso that if X is CH2, n is not 1, and a method for their preparation. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

The invention discloses a O, O-dimethyl-O-[-3-methyl-4-amino phenyl] thionic phosphate (FNH2) as fenitrothion hapten, artificial antigen and specific antibody, which is characterized by the following: reducing nitro in the fenitrothion molecular structure into amino under acid condition with zinc powder; reacting to obtain the hapten molecule in connection with carrier protein; diazotizing to couple hapten and protein to obtain immunogen and peridium; using immune animal with immunogen to make the specific antibody.